# 1 Nutropin Depot<sup>®</sup>

# 2 [somatropin (rDNA origin) for injectable suspension]

#### 3 **DESCRIPTION**

- 4 Nutropin Depot<sup>®</sup> [somatropin (rDNA origin) for injectable suspension] is a long-acting
- 5 dosage form of recombinant human growth hormone (rhGH). Somatropin has
- 6 191 amino acid residues and a molecular weight of 22,125 daltons. The amino acid
- 7 sequence of the product is identical to that of pituitary-derived human growth hormone.
- 8 The protein is synthesized by a specific laboratory strain of *E. coli* as a precursor
- 9 consisting of the rhGH molecule preceded by the secretion signal from an
- 10 E. coli protein. This precursor is directed to the plasma membrane of the cell. The
- 11 signal sequence is removed and the native protein is secreted into the periplasm so that
- 12 the protein is folded appropriately as it is synthesized.
- 13 Somatropin is a highly purified preparation. Biological potency is determined using a
- 14 cell proliferation bioassay.
- 15 The Nutropin Depot formulation consists of micronized particles of rhGH embedded in
- 16 biocompatible, biodegradable polylactide-coglycolide (PLG) microspheres. Nutropin
- 17 Depot is packaged in vials as a sterile, white to off-white, preservative-free, free-flowing
- 18 powder. Before administration, the powder is suspended in Diluent for Nutropin Depot
- 19 (a sterile aqueous solution).
- Each 13.5 mg 3 cc single-use vial of Nutropin Depot contains 13.5 mg somatropin,
- 21 1.2 mg zinc acetate, 0.8 mg zinc carbonate, and 68.9 mg PLG.
- 22 Each 18 mg 3 cc single-use vial of Nutropin Depot contains 18 mg somatropin,
- 23 1.6 mg zinc acetate, 1.1 mg zinc carbonate, and 91.8 mg PLG.
- Each 22.5 mg 3 cc single-use vial of Nutropin Depot contains 22.5 mg somatropin,
- 25 2.0 mg zinc acetate, 1.4 mg zinc carbonate, and 114.8 mg PLG.
- Each dosage size contains an overage of rhGH microspheres to ensure delivery oflabeled contents.
- Each 1.5 mL single-use vial of Diluent for Nutropin Depot contains 30 mg/mL
- 29 carboxymethylcellulose sodium salt, 1 mg/mL polysorbate 20, 9 mg/mL sodium chloride,
- 30 and sterile water for injection; pH 5.8–7.2.

# 31 CLINICAL PHARMACOLOGY

#### 32 General

- 33 In vivo preclinical and clinical testing has demonstrated that growth hormone (GH)
- 34 stimulates longitudinal bone growth and elevates insulin-like growth factor-I (IGF-I)
- 35 levels.
- 36 Actions that have been demonstrated for hGH include:

37 A. Tissue Growth - 1) Skeletal Growth: GH stimulates skeletal growth in pediatric 38 patients with growth failure due to a lack of adequate secretion of endogenous GH. 39 Skeletal growth is accomplished at the epiphyseal plates at the ends of a growing 40 bone. Growth and metabolism of epiphyseal plate cells are directly stimulated by 41 GH and one of its mediators, IGF-I. Serum levels of IGF-I are low in children and 42 adolescents who are growth hormone deficient (GHD), but increase during 43 treatment with GH. In pediatric patients, new bone is formed at the epiphyses in response to GH and IGF-I. This results in linear growth until these growth plates 44 45 fuse at the end of puberty. 2) Cell Growth: Treatment with hGH results in an 46 increase in both the number and the size of skeletal muscle cells. 3) Organ Growth: 47 GH increases the size of internal organs, including kidneys, and increases red cell 48 mass. Treatment of hypophysectomized or genetic dwarf rats with GH results in 49 increases in organ and overall body growth. In normal rats subjected to 50 nephrectomy-induced uremia, GH promoted skeletal and body growth.

- B. Protein Metabolism Linear growth is facilitated in part by GH-stimulated protein
   synthesis. This is reflected by nitrogen retention as demonstrated by a decline in
   urinary nitrogen excretion and blood urea nitrogen during GH therapy.
- 54 C. Carbohydrate Metabolism - GH is a modulator of carbohydrate metabolism. 55 Patients with inadequate endogenous secretion of GH sometimes experience 56 fasting hypoglycemia that is improved by treatment with GH. GH therapy may 57 decrease insulin sensitivity. Administration of hGH formulated for daily dosing 58 resulted in increased mean fasting and postprandial insulin levels, more commonly 59 in overweight or obese individuals. Mean trough levels for fasting and postprandial 60 insulin were unchanged after 3 or 6 months of Nutropin Depot therapy in GHD 61 children. As with daily GH, mean trough levels for fasting glucose, postprandial glucose, and hemoglobin A<sub>1c</sub> remained unchanged after 3 or 6 months of Nutropin 62 63 Depot therapy.
- **D. Lipid Metabolism** In GHD patients, administration of GH formulated for daily
   dosing resulted in lipid mobilization, reduction in body fat stores, increased plasma
   fatty acids, and decreased plasma cholesterol levels.

67 E. Mineral Metabolism - The retention of total body potassium in response to 68 GH administration apparently results from cellular growth. Serum levels of 69 inorganic phosphorus may increase slightly in patients with inadequate secretion of 70 endogenous GH due to metabolic activity associated with bone growth as well as 71 increased tubular reabsorption of phosphate by the kidney. Serum calcium is not 72 significantly altered in these patients. Sodium retention also occurs. (See 73 PRECAUTIONS: Laboratory Tests.) GH therapy results in increases in serum 74 alkaline phosphatase.

F. Connective Tissue Metabolism - GH stimulates the synthesis of chondroitin
 sulfate and collagen as well as the urinary excretion of hydroxyproline.

#### 77 Pharmacokinetics


78 Nutropin Depot is a long-acting dosage form of somatropin designed to be administered

- by subcutaneous (SC) injection once or twice monthly. Following the injection, bioactive
- 80 rhGH is released from the microspheres into the SC environment initially by diffusion,
- 81 followed by both polymer degradation and diffusion. Although no studies have been
- 82 performed that address the distribution, elimination, or metabolism of Nutropin Depot,
- 83 once released and absorbed the rhGH is believed to be distributed and eliminated in a
- 84 manner similar to somatropin formulated for daily administration.
- 85 The serum hGH concentration-time profiles of single doses of 0.75 mg/kg and
- 86 1.5 mg/kg of Nutropin Depot have been characterized in pediatric GHD patients (refer to
- 87 Figure 1). The in vivo profiles are characterized by an initial rapid release followed by a
- slow decline in GH concentration. Both the maximum concentrations achieved  $(C_{max})$
- and total exposure (AUC<sub>0-28 days</sub>) appear to be proportional to dose. Serum hGH levels
- greater than 1  $\mu$ g/L persist for approximately 11–14 days postdose for the two doses.
- 91 Repeated dosing of Nutropin Depot over 6 months showed no progressive
- 92 accumulation of GH.
- 93 Absorption-In a study of Nutropin Depot in pediatric patients with GHD, an SC dose of
- 94 0.75 mg/kg (n=12) or 1.5 mg/kg (n=8) was administered. The mean  $\pm$  SD hGH C<sub>max</sub>
- 95 values were 48±26  $\mu$ g/L and 90±23  $\mu$ g/L, respectively, at 12–13 hours postdose. The
- 96 corresponding AUC<sub>0-28 days</sub> values were  $83\pm49 \ \mu\text{g} \cdot \text{day/L}$  and  $140\pm34 \ \mu\text{g} \cdot \text{day/L}$ ,
- 97 respectively, for the two doses. For the 0.75 mg/kg and 1.5 mg/kg doses, the AUC<sub>0-2days</sub>
- 98 accounted for approximately 52 $\pm$ 16 percent and 61 $\pm$ 10 percent of the total AUC<sub>0-28 days</sub>,
- 99 respectively. Estimates of relative bioavailability in GHD children for a single dose of
- 100 Nutropin Depot ranged from 33% to 38% when compared to a single dose of Nutropin
- 101 AQ® [somatropin (rDNA origin) injection] in healthy adults, and from 48% to 55% when
- 102 compared to chronically dosed Protropin® (somatrem for injection) in GHD children.

- 103 Distribution—Animal studies with rhGH formulated for daily administration showed that
- 104 GH localizes to highly perfused organs, particularly the liver and kidney. The volume of
- 105 distribution at steady state for rhGH formulated for daily administration in healthy adult
- 106 males is about 50 mL/kg body weight, approximating the serum volume.
- 107 Metabolism—Both the liver and kidney have been shown to be important metabolizing
- 108 organs for GH. Animal studies using rhGH formulated for daily administration suggest
- 109 that the kidney is the dominant organ of clearance. GH is filtered at the glomerulus and
- 110 reabsorbed in the proximal tubules. It is then cleaved within renal cells into its
- 111 constituent amino acids, which return to the systemic circulation.
- 112 Elimination—The mean terminal  $t_{1/2}$  after intravenous (IV) administration of rhGH
- 113 formulated for daily administration in healthy adult males is estimated to be
- 114 19.5±3.1 minutes. Clearance of rhGH after IV administration in healthy adults and
- 115 children is reported to be in the range of 116–174 mL/hr/kg.
- 116 117

118

Figure 1 Single-Dose Mean (SD) GH Concentrations in Pediatric GHD Patients



119 120



#### 121 Special Populations

- Pediatric—Available literature data suggest that rhGH clearances are similar in adultsand children.
- 124 Gender—Following administration of either 0.75 mg/kg or 1.5 mg/kg Nutropin Depot,
- 125 Day 1 GH levels were higher in females compared to males. No relationship was
- 126 observed between gender and pharmacodynamic marker (IGF-I and IGFBP-3) levels.
- 127 Race—The effect of race on Nutropin Depot disposition is unknown due to the limited
- 128 number of non-Caucasian patients in the Nutropin Depot studies.
- 129 Growth Hormone Deficiency—Nutropin Depot has not been studied in healthy adults or
- 130 children. However, reported values for clearance of rhGH formulated for daily
- 131 administration in adults and children with GHD range from 138–245 mL/hr/kg and are
- 132 similar to those observed in healthy adults and children. Mean terminal  $t_{1/2}$  values
- 133 following IV and SC administration in adult and pediatric patients with GHD are also
- 134 similar to those observed in healthy adult males.
- 135 Renal Insufficiency—Nutropin Depot has not been studied in patients with renal
- 136 insufficiency. Children and adults with chronic renal failure (CRF) and end-stage renal
- 137 disease (ESRD) tend to have decreased clearance of rhGH formulated for daily
- administration compared with normals. Endogenous GH production may also increase
- in some individuals with ESRD. However, no GH accumulation has been reported in
- 140 children with CRF or ESRD dosed with daily regimens.
- 141 Hepatic Insufficiency—Nutropin Depot has not been studied in patients with hepatic
- 142 insufficiency. A reduction in clearance of rhGH formulated for daily administration has
- been noted in patients with severe liver dysfunction. The clinical significance of this
- 144 decrease is unknown.

# 145 Pharmacodynamics


- 146 IGF-I levels peaked between 1.5 and 3.5 days postdose and remained above baseline
- 147 for approximately 16 to 20 days, confirming GH activity for an extended period.
- 148 Repeated dosing of Nutropin Depot over 6 months showed no progressive
- accumulation of IGF-I (as shown in Figure 2) or IGF-binding protein 3 (IGFBP-3).
- 150

# 151

153

# 152

#### Figure 2 Repeated-Dose Mean (SD) IGF-I Concentrations in Pediatric GHD Patients



- 154
- 155

#### 156 Efficacy Studies

# 157 Pediatric Growth Hormone Deficiency (GHD)

158 In two multicenter, open-label clinical studies in prepubertal children (mean age (± SD)

- 159 7.4±2.8) with idiopathic or organic GHD previously untreated with rhGH, 91 patients
- 160 were treated with Nutropin Depot at 1.5 mg/kg once monthly or 0.75 mg/kg twice
- 161 monthly by subcutaneous injection for up to six months. (See DOSAGE AND
- 162 ADMINISTRATION for the number of injections required per dose.) The mean prestudy
- 163 growth rate was 4.8±2.4 cm/yr (n=89). The dose-pooled, mean 6-month annualized
- 164 growth rate on Nutropin Depot therapy was 8.4±2.2 cm/yr (n=89).
- Seventy-six patients continued treatment in an extension study. For patients who
  completed 12 months the mean growth rate was 7.8±1.9 cm/yr for the two dose groups
- 167 combined (n=69). Mean height SD score changed from -3.0±1.0 prestudy to -2.5±0.9 at
- 168 Month 12 (n=69). The mean 0 to 12 month change in bone age was 1.0±0.4 years
- 169 (n=63). During the long-term extension study, fourteen of seventy-five (19%) patients
- 170 discontinued due to dissatisfaction with growth response. Historical studies of GHD
- 171 children treated with daily Protropin® (somatrem for injection) or Nutropin® [somatropin
- 172 (rDNA origin) for injection] injections for 12 months at 0.3 mg/kg weekly had the

- 173 following mean values: baseline growth rate 3.6 to 4.8 cm/yr; first year growth rate 10.1
- to 11.3 cm/yr; first year change in bone age 1.1 to 1.5 years.
- 175 In a dose-ranging study, 24 patients previously treated with daily GH (mean age
- 176 9.6±2.2 years; mean duration of prior GH therapy 2.8±1.6 yr, range 0.9 to 6.1 yr) were
- 177 switched to Nutropin Depot therapy at the above doses. The mean growth rate on
- previous treatment was 8.2±3.0 cm/yr (range 3.2 to 13.1 cm/yr) and on Nutropin Depot
- 179 was 5.1±2.0 cm/yr (range 2.4 to 9.6 cm/yr). During a long-term extension study, four of
- 180 ten previously treated patients discontinued due to dissatisfaction with growth response.
- 181 Historical studies of GHD children (n=181) treated with daily Protropin or Nutropin at a
- 182 dose of 0.3 mg/kg weekly had the following mean growth rates: first year growth rate
- 183 9.7 to 11.4 cm/yr; second year growth rate 8.1 to 8.9 cm/yr; third year growth rate 7.5 to
- 184 7.8 cm/yr; fourth year growth rate 6.6 to 7.1 cm/yr.

# 185 INDICATIONS AND USAGE

- 186 Nutropin Depot<sup>®</sup> [somatropin (rDNA origin) for injectable suspension] is indicated for the
- 187 long-term treatment of growth failure due to a lack of adequate endogenous
- 188 GH secretion.
- 189 <u>Considerations for use</u>:—As with any GH treatment, patients should be monitored
- 190 closely throughout therapy for growth response to Nutropin Depot. Failure to respond
- adequately requires careful assessment, as described under DOSAGE AND
- 192 ADMINISTRATION. Patients for whom no discernible cause is found should be
- 193 considered for a course of treatment with a daily form of rhGH. Experience in patients
- 194 who were treated with daily GH and switched to Nutropin Depot is limited.

# 195 (CONTRAINDICATIONS)

- 196 Growth hormone should not be initiated to treat patients with acute critical illness due to
- 197 complications following open heart or abdominal surgery, multiple accidental trauma, or
- 198 to patients having acute respiratory failure. Two placebo-controlled clinical trials in
- 199 non-growth hormone–deficient adult patients (n=522) with these conditions revealed a
- significant increase in mortality (41.9% vs. 19.3%) among somatropin-treated patients
- 201 (doses 5.3–8 mg/day) compared to those receiving placebo (see WARNINGS).
- 202 Nutropin Depot should not be used for growth promotion in pediatric patients with203 closed epiphyses.
- Nutropin Depot should not be used in patients with active neoplasia. GH therapy should be discontinued if evidence of neoplasia develops.

- 206 Growth hormone is contraindicated in patients with Prader-Willi syndrome who are
- 207 severely obese or have severe respiratory impairment (see WARNINGS). Unless
- 208 patients with Prader-Willi syndrome also have a diagnosis of growth hormone
- 209 deficiency, Nutropin Depot is not indicated for the long term treatment of pediatric
- 210 patients who have growth failure due to genetically confirmed Prader-Willi syndrome.

Revised language per FDA letter dated 30 March

#### 211 WARNINGS

- 212 See CONTRAINDICATIONS for information on increased mortality in patients with
- 213 acute critical illnesses in intensive care units due to complications following open heart
- or abdominal surgery, multiple accidental trauma, or with acute respiratory failure. The
- 215 safety of continuing growth hormone treatment in patients receiving replacement doses
- 216 for approved indications who concurrently develop these illnesses has not been
- established. Therefore, the potential benefit of treatment continuation with growthhormone in patients having acute critical illnesses should be weighed against the
- hormone in patients having acute critical illnesses should be weighed against the
- 219 potential risk.
- 220 There have been reports of fatalities after initiating therapy with growth hormone in
- 221 pediatric patients with Prader-Willi syndrome who had one or more of the following risk
- 222 factors: severe obesity, history of upper airway obstruction or sleep apnea, or
- 223 unidentified respiratory infection. Male patients with one or more of these factors may
- be at greater risk than females. Patients with Prader-Willi syndrome should be
- evaluated for signs of upper airway obstruction and sleep apnea before initiation of
- treatment with growth hormone. If, during treatment with growth hormone, patients
- show signs of upper airway obstruction (including onset of or increased snoring) and/or
- new onset sleep apnea, treatment should be interrupted. All patients with Prader-Willi
- syndrome treated with growth hormone should also have effective weight control and be monitored for signs of respiratory infection, which should be diagnosed as early as
- 231 possible and treated aggressively (see CONTRAINDICATIONS). Unless patients with
- 232 Prader-Willi syndrome also have a diagnosis of growth hormone deficiency, Nutropin
- 232 Prader-Will syndrome also have a diagnosis of growth normone deficiency, Nutropin Revised language 233 Depot is not indicated for the long term treatment of pediatric patients who have growthper FDA letter
- 234 failure due to genetically confirmed Prader-Willi syndrome.

#### 235 **PRECAUTIONS**

- 236 General: Nutropin Depot should be prescribed by physicians experienced in the
- 237 diagnosis and management of patients with GHD.
- Because GH may reduce insulin sensitivity, patients should be monitored for evidenceof glucose intolerance.
- 240 For patients with diabetes mellitus, the insulin dose may require adjustment when
- 241 GH therapy is instituted. Because GH may reduce insulin sensitivity, particularly in

Nutropin Depot - Genentech, Inc. 21075\_S008\_annotated\_OCT2004

dated 30 March

- 242 obese individuals, patients should be observed for evidence of glucose intolerance.
- 243 Patients with diabetes or glucose intolerance should be monitored closely during
- GH therapy.
- 245 Patients with symptomatic hypoglycemia associated with GHD should be
- closely monitored.
- 247 Patients with a history of an intracranial lesion should be examined frequently for
- 248 progression or recurrence of the lesion. In pediatric patients, clinical literature has
- 249 demonstrated no relationship between GH replacement therapy and central nervous
- 250 system (CNS) tumor recurrence or new extracranial tumors.
- Slipped capital femoral epiphysis may occur more frequently in patients with endocrinedisorders or in patients undergoing rapid growth.
- Progression of scoliosis can occur in patients who experience rapid growth. Because
  GH increases growth rate, patients with a history of scoliosis who are treated with GH
- should be monitored for progression of scoliosis. GH has not been shown to increase
- the incidence of scoliosis.
- 257 Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea,
- and/or vomiting has been reported in a small number of patients treated with
- 259 GH products. Symptoms usually occurred within the first 8 weeks of the initiation of
- 260 GH therapy. In all reported cases, IH-associated signs and symptoms resolved after
- termination of therapy or a reduction of the GH dose. Funduscopic examination of
- 262 patients is recommended at the initiation and periodically during the course of 263 GH therapy
- GH therapy.
- As with any protein, local or systemic allergic reactions may occur. Parents/Patients should be informed that such reactions are possible and that prompt medical attention should be sought if allergic reactions occur (see ADVERSE REACTIONS).
- Laboratory Tests: Serum levels of inorganic phosphorus, alkaline phosphatase, and parathyroid hormone (PTH) may increase with GH therapy.
- 269 Untreated hypothyroidism prevents optimal response to GH. Changes in thyroid
- 270 hormone laboratory measurements may develop during GH treatment. Therefore,
- 271 patients should have periodic thyroid function tests and should be treated with thyroid
- hormone when indicated.

- 273 Drug Interactions: Excessive glucocorticoid therapy will inhibit the growth-promoting
- 274 effect of human GH. Patients with ACTH deficiency should have their glucocorticoid-
- 275 replacement dose carefully adjusted to avoid an inhibitory effect on growth.

276 Limited published data indicate that GH treatment increases cytochrome P450 (CP450)

- 277 mediated antipyrine clearance in humans. These data suggest that GH administration
- 278 may alter the clearance of compounds known to be metabolized by CP450 liver 279 enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). Careful
- 280
- monitoring is advisable when GH is administered in combination with other drugs known
- 281 to be metabolized by CP450 liver enzymes.
- 282 Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenicity, mutagenicity, 283 and fertility studies have not been conducted with Nutropin Depot.
- 284 Pregnancy Category C: Animal reproduction studies have not been conducted with
- 285 Nutropin Depot. It is also not known whether Nutropin Depot can cause fetal harm
- 286 when administered to a pregnant woman or can affect reproduction capacity. Nutropin
- 287 Depot should be given to a pregnant woman only if clearly needed.
- 288 Nursing Mothers: It is not known whether GH is excreted in human milk. Because 289 many drugs are excreted in human milk, caution should be exercised when Nutropin 290 Depot is administered to a nursing mother.
- 291 Information for Patients: Patients being treated with Nutropin Depot and/or their parents
- 292 should be informed of the potential benefits and risks associated with treatment. If
- 293 home use is determined to be desirable by the physician, instructions on appropriate
- 294 use should be given, including a review of the contents of the Patient Information Insert.
- 295 This information is intended to aid in the safe and effective administration of the
- 296 medication. It is not a disclosure of all possible adverse or intended effects.
- 297 If home use is prescribed, a puncture-resistant container for the disposal of used
- 298 syringes and needles should be recommended to the patient. Patients and/or parents
- 299 should be thoroughly instructed in the importance of proper disposal and cautioned
- 300 against any reuse of needles and syringes (see Patient Information Insert).

#### 301 **ADVERSE REACTIONS**

- 302 As with all protein pharmaceuticals, patients may develop antibodies to the protein. GH
- 303 antibody-binding capacities below 2 mg/L have not been associated with growth
- 304 attenuation. In some cases when binding capacity exceeds 2 mg/L, growth attenuation
- 305 has been observed. In clinical studies of pediatric patients who were treated with
- 306 Nutropin Depot, 0/138 patients with GHD screened for antibody production developed

- antibodies with binding capacities  $\geq 2$  mg/L at any time during a treatment period of up to 17.4 months.
- 309 In addition to an evaluation of compliance with the prescribed treatment program and
- thyroid status, testing for antibodies to GH should be carried out in any patient who fails
- to respond to therapy.
- 312 In studies involving 138 pediatric patients treated with Nutropin Depot, the most
- 313 frequent adverse reactions were injection-site reactions, which occurred in nearly all
- 314 patients. On average, 2 to 3 injection-site adverse reactions were reported per
- injection. These reactions included nodules (61% of injections), erythema (53%), pain
- 316 post-injection (47%), pain during injection (43%), bruising (20%), itching (13%),
- 317 lipoatrophy (13%), and swelling or puffiness (8%). The intensity of these reactions was
- 318 generally rated mild to moderate, with pain during injection occasionally rated as severe
- 319 (7%).
- 320 Adverse reactions observed less frequently in the Nutropin Depot studies which were
- 321 considered possibly, probably, or definitely related to the drug by the treating physician
  322 (usually occurring 1–3 days postdose) included: headache (13% of subjects), nausea
  323 (8%), lower extremity pain (7%), fever (7%), and vomiting (5%). These symptoms were
  324 generally self-limited and well-tolerated. One patient experienced a generalized body
- rash that was most likely an allergic reaction to Nutropin Depot.
- Leukemia has been reported in a small number of GHD patients treated with GH. It is uncertain whether this increased risk is related to the pathology of GH deficiency itself,
- 328 GH therapy, or other associated treatments such as radiation therapy for intracranial
- 329 tumors. On the basis of current evidence, experts cannot conclude that GH therapy is
- 330 responsible for these occurrences.
- 331 Other adverse drug reactions that have been reported in GH-treated patients include
- the following: 1) Metabolic: mild, transient peripheral edema; 2) Musculoskeletal:
- arthralgia, carpal tunnel syndrome; 3) Skin: rare increased growth of pre-existing nevi;
- patients should be monitored for malignant transformation; 4) Endocrine:
- 335 gynecomastia; and 5) Rare pancreatitis. Of these reactions, only edema (<1% of
- patients) and arthralgia (4%) were reported as related to drug in the Nutropin Depot
- 337 studies.

# 338 OVERDOSAGE

- 339 The recommended dosage of Nutropin Depot should not be exceeded. Acute
- 340 overdosage could lead to fluid retention, headache, nausea, vomiting, and/or
- 341 hyperglycemia. Long-term overdosage could result in signs and symptoms of gigantism

Nutropin Depot - Genentech, Inc. 21075\_S008\_annotated\_OCT2004

- and/or acromegaly, consistent with the known effects of excess GH.
- 343 (See recommended dosage instructions given below.)

#### 344 DOSAGE AND ADMINISTRATION

345 The Nutropin Depot dosage and administration schedule should be individualized for

346 each patient. Response to GH therapy in pediatric patients tends to decrease over

347 time. However in pediatric patients, failure to increase growth rate, particularly during

the first year of therapy, suggests the need for close assessment of compliance and

evaluation of other causes of growth failure, such as hypothyroidism, undernutrition, and

- advanced bone age.
- 351 Once-Monthly Injection—It is recommended that an SC injection at a dosage of
- 352 1.5 mg/kg body weight be administered on the same day of each month. Dosages

above the recommended once-monthly regimen have not been studied in clinical trials.

354 Note: subjects over 15 kg will require more than one injection per dose.

355 *Twice-Monthly Injections*—It is recommended that an SC injection at a dosage of

356 0.75 mg/kg body weight be administered twice each month on the same days of each

- 357 month (e.g., Days 1 and 15 of each month). Dosages above the recommended
- 358 twice-monthly regimen have not been studied in clinical trials. Note: subjects over 30 kg
- 359 will require more than one injection per dose.

360	The table below indicates	the required	number of injections per do	se.
-----	---------------------------	--------------	-----------------------------	-----

	Number of Injections Per Dose		
Patient Weight (kg)	0.75 mg/kg twice monthly	1.5 mg/kg once monthly	
≤15	1	1	
>15-30	1	2	
>30-45	2	3	
>45-60	2	*	
>60	3	*	

361 362 \*Twice-monthly dosing recommended

# 363 **Preparation of Dose**

Nutropin Depot powder may **only** be suspended in Diluent for Nutropin Depot suppliedin the kit and administered with the supplied needles.

Using the chart below, determine the volume of diluent needed to suspend Nutropin
 Depot. Withdraw the diluent into a 3 cc syringe using the needle supplied in the kit.
 Only the diluent supplied in the kit should be used for reconstitution, and any
 remaining diluent should be discarded.

Nutropin Depot - Genentech, Inc. 21075\_S008\_annotated\_OCT2004

Vial Size (mg somatropin)	Volume of Diluent to Be Added (mL)
13.5	0.8
18	1.0
22.5	1.2

Note: Since the suspension is viscous and prevents complete withdrawal of the entire vial contents, the vials are overfilled to ensure delivery of the labeled amount of somatropin. Using these diluent volumes for final suspension results in a final concentration of 19 mg/mL somatropin in each vial size.

370

- Inject the diluent into the vial against the vial wall. Swirl the vial vigorously for up to
  2 minutes to disperse the powder in the diluent. Mixing is complete when the
  suspension appears uniform, thick, and milky, and all the powder is fully dispersed.
  Do not store the vial after reconstitution or the suspension may settle.
- 375 3. Withdraw the required dose. Only one vial should be used for each injection.
  376 Replace the needle with a new needle from the kit and administer the dose
  377 immediately to avoid settling of the suspension in the syringe. Deliver the dose
  378 from the syringe at a continuous rate over not more than 5 seconds. Discard
  379 unused vial contents as the product contains no preservative. An extra needle has
  380 been provided in the kit.

# 381 Stability and Storage

- 382 Before Suspension—Nutropin Depot and diluent vials must be stored at 2–8°C/36–46°F
- 383 (under refrigeration). Avoid freezing the vials of Nutropin Depot and Diluent for
- **Nutropin Depot**. Do not expose the Nutropin Depot vial to temperatures above
- $25^{\circ}C$  (77°F). Expiration dates are stated on the labels.
- 386 *After Suspension*—Because Nutropin Depot contains no preservatives, all injections
- 387 must be given immediately. Do not allow the suspension to settle prior to withdrawal of
- the dose. Suspended solution cannot be stored or used to suspend another vial of
- 389 Nutropin Depot.

# 390 How Supplied

- Nutropin Depot is supplied as single-use vials with 13.5 mg, 18 mg, or 22.5 mg sterile,
  preservative-free somatropin powder per vial.
- Each 13.5 mg kit contains one single-use 13.5 mg vial of Nutropin Depot<sup>®</sup> [somatropin
- (rDNA origin) for injectable suspension], one 1.5 mL single-use vial of Diluent for
- Nutropin Depot, and three 21-gauge, 1/2" needles: NDC 50242-032-35.

- 396 Each 18 mg kit contains one single-use 18 mg vial of Nutropin Depot<sup>®</sup> [somatropin
- 397 (rDNA origin) for injectable suspension], one 1.5 mL single-use vial of Diluent for
- Nutropin Depot, and three 21-gauge, 1/2" needles: NDC 50242-034-41.
- 399 Each 22.5 mg kit contains one single-use 22.5 mg vial of Nutropin Depot<sup>®</sup> [somatropin
- 400 (rDNA origin) for injectable suspension], one 1.5 mL single-use vial of Diluent for
- 401 Nutropin Depot, and three 21-gauge, 1/2" needles: NDC 50242-036-54.

Nutropin Depot<sup>®</sup> [somatropin (rDNA origin) for injectable suspension]

# Nutropin Depot<sup>™</sup> [somatropin (rDNA origin) for injectable suspension] and Diluent for Nutropin Depot are manufactured for:

Genentech, Inc. 1 DNA Way South San Francisco, CA 94080-4990 <sup>©</sup>1999 Genentech, Inc.

4819504 FDA Approval Date December 1999) Code Revision Date October 2004

402

403